Evidence map›Paper›PMID 27470079›Full record

ArticleThe Lancet. Oncology2016

Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study.

Zheng Li, Yi Xia, Li-Na Feng, Jie-Rong Chen, Hong-Min Li, Jing Cui, Qing-Qing Cai, Kar Seng Sim, Maarja-Liisa Nairismägi, Yurike Laurensia and 36 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026
    Review
  7. Epidemiology of mature T-cell and NK-cell neoplasms: east and west.The Lancet regional health. Western Pacific · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Types of T-cell lymphoma-a cytogenetic perspective.Annals of medicine and surgery (2012) · 2022
    Article
  17. Article
  18. How we treat NK/T-cell lymphomas.Journal of hematology & oncology · 2022
    Review
  19. Review
  20. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 16 institutions in 7 countries.

Zheng LiSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Genome Institute of Singapore, Singapore.
Yi XiaSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Li-Na FengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Jie-Rong ChenSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Hong-Min LiState Key Laboratory of Molecular Oncology, Beijing, China; Department of Etiology and Carcinogenesis, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, Beijing, China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jing CuiDivision of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Qing-Qing CaiSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Kar Seng SimGenome Institute of Singapore, Singapore.
Maarja-Liisa NairismägiLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Yurike LaurensiaLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Wee Yang MeahGenome Institute of Singapore, Singapore.
Wen-Sheng LiuSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Yun-Miao GuoSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Li-Zhen ChenSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Qi-Sheng FengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chi Pui PangDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Li Jia ChenDepartment of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Soo Hong ChewDepartment of Economics, National University of Singapore, Singapore.
Richard P EbsteinDepartment of Psychology, National University of Singapore, Singapore.
Jia Nee FooGenome Institute of Singapore, Singapore.
Jianjun LiuGenome Institute of Singapore, Singapore.
Jeslin HaLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Lay Poh KhooLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Suk Teng ChinLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Yi-Xin ZengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Beijing Hospital, Beijing, China.
Tin AungSingapore Eye Research Institute, Singapore.
Balram ChowbayLaboratory of Clinical Pharmacology, Division of Medical Sciences, Humphrey Oei Institute of Cancer Research, National Cancer Centre, Singapore; Clinical Pharmacology, SingHealth, Singapore; Office of Clinical Sciences, Duke-National University of Singapore Medical School, Singapore.
Colin Phipps DiongDepartment of Haematology, Singapore General Hospital, Singapore.
Fen ZhangDepartment of Pathology, Guangdong General Hospital, Guangzhou, China.
Yan-Hui LiuDepartment of Pathology, Guangdong General Hospital, Guangzhou, China.
Tiffany TangDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Miriam TaoDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Richard QuekDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Farid MohamadDivision of Medical Oncology, National Cancer Centre Singapore, Singapore.
Soo Yong TanDivision of Medical Oncology, National Cancer Centre Singapore, Singapore; Department of Pathology, Singapore General Hospital, Singapore; Institute of Molecular and Cell Biology, A*STAR, Singapore; Department of Pathology, University of Malaya, Kuala Lumpur, Malaysia; Department of Pathology, National University of Singapore, Singapore.
Bin Tean TehProgram in Cancer and Stem Cell Biology, Duke-National University of Singapore Medical School, Singapore; Institute of Molecular and Cell Biology, A*STAR, Singapore; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore.
Siok Bian NgDepartment of Pathology, National University of Singapore, Singapore; Cancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Pathology, National University Hospital, National University Health System, Singapore.
Wee Joo ChngCancer Science Institute of Singapore, National University of Singapore, Singapore; Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore.
Choon Kiat OngLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore.
Yukinori OkadaDepartment of Human Genetics and Disease Diversity, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan; Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Soumya RaychaudhuriDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Partners Center for Personalized Genetic Medicine, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Institute of Inflammation and Repair, University of Manchester, Manchester, UK; Rheumatology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
Soon Thye LimLymphoma Genomic Translational Research Laboratory, National Cancer Centre Singapore, Singapore; Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Office of Education, Duke-National University of Singapore Medical School, Singapore.
Wen TanState Key Laboratory of Molecular Oncology, Beijing, China; Department of Etiology and Carcinogenesis, Beijing Key Laboratory for Carcinogenesis and Cancer Prevention, Beijing, China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Rou-Jun PengSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Chiea Chuen KhorGenome Institute of Singapore, Singapore; Singapore Eye Research Institute, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Jin-Xin BeiSun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Genome Institute of Singapore, Singapore; Center for Precision Medicine, Sun Yat-Sen University, Guangzhou, China. Electronic address: beijx@sysucc.org.cn.
National Cancer Centre Singapore · SGNational University of Singapore · SGState Key Laboratory of Oncology in South ChinaGenome Institute of Singapore · SGSun Yat-sen University Cancer Center · CNSun Yat-sen University · CNChinese University of Hong Kong · CNGuangdong General Hospital · CNNational University Health System · SGBeijing National Laboratory for Molecular Sciences · CNBrigham and Women's Hospital · USBroad Institute · USRIKEN Center for Integrative Medical Sciences · JPSingapore Eye Research Institute · SGSingapore General Hospital · SGState Key Laboratory of Molecular Oncology

Funding

Genetic predictors of response to anti-TNF therapy in rheumatoid arthritisU01GM092691 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2010 to 2014
$7.5M
Discovery and Functional Impact of Common and Rare Variants in RAR01AR063759 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Soumya Raychaudhuri · 2013 to 2026
$5.4M
Fine-mapping the MHC associations in rheumatoid arthritis from GWAS dataR01AR062886 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI RAYCHAUDHURI, SOUMYA · 2012 to 2013
$783k
NIAMS NIH HHS R01 AR062886NIAMS NIH HHS R01 AR063759NIGMS NIH HHS U01 GM092691
6 · The paper itself

Abstract

backgroundExtranodal natural killer T-cell lymphoma (NKTCL), nasal type, is a rare and aggressive malignancy that occurs predominantly in Asian and Latin American populations. Although Epstein-Barr virus infection is a known risk factor, other risk factors and the pathogenesis of NKTCL are not well understood. We aimed to identify common genetic variants affecting individual risk of NKTCL.

methodsWe did a genome-wide association study of 189 patients with extranodal NKTCL, nasal type (WHO classification criteria; cases) and 957 controls from Guangdong province, southern China. We validated our findings in four independent case-control series, including 75 cases from Guangdong province and 296 controls from Hong Kong, 65 cases and 983 controls from Guangdong province, 125 cases and 1110 controls from Beijing (northern China), and 60 cases and 2476 controls from Singapore. We used imputation and conditional logistic regression analyses to fine-map the associations. We also did a meta-analysis of the replication series and of the entire dataset.

findingsAssociations exceeding the genome-wide significance threshold (p<5 × 10(-8)) were seen at 51 single-nucleotide polymorphisms (SNPs) mapping to the class II MHC region on chromosome 6, with rs9277378 (located in HLA-DPB1) having the strongest association with NKTCL susceptibility (p=4·21 × 10(-19), odds ratio [OR] 1·84 [95% CI 1·61-2·11] in meta-analysis of entire dataset). Imputation-based fine-mapping across the class II MHC region suggests that four aminoacid residues (Gly84-Gly85-Pro86-Met87) in near-complete linkage disequilibrium at the edge of the peptide-binding groove of HLA-DPB1 could account for most of the association between the rs9277378*A risk allele and NKTCL susceptibility (OR 2·38, p value for haplotype 2·32 × 10(-14)). This association is distinct from MHC associations with Epstein-Barr virus infection.

interpretationTo our knowledge, this is the first time that a genetic variant conferring an NKTCL risk is noted at genome-wide significance. This finding underlines the importance of HLA-DP antigen presentation in the pathogenesis of NKTCL.

fundingTop-Notch Young Talents Program of China, Special Support Program of Guangdong, Specialized Research Fund for the Doctoral Program of Higher Education (20110171120099), Program for New Century Excellent Talents in University (NCET-11-0529), National Medical Research Council of Singapore (TCR12DEC005), Tanoto Foundation Professorship in Medical Oncology, New Century Foundation Limited, Ling Foundation, Singapore National Cancer Centre Research Fund, and the US National Institutes of Health (1R01AR062886, 5U01GM092691-04, and 1R01AR063759-01A1).

Indexed as

Genetic Predisposition to DiseaseGenome-Wide Association StudyAdultAgedBiomarkers, TumorCase-Control StudiesChinaFemaleFollow-Up StudiesHumansLymphoma, Extranodal NK-T-CellMaleMiddle AgedNeoplasm StagingPolymorphism, Single NucleotidePrognosisBiomarkers, Tumor

Identifiers

PMID27470079
PMCPMC6790270
OpenAlexW2494220216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.